Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
作者： Andreas Burchert , Martin C. Müller , Philippe Kostrewa , Philipp Erben , Tilman Bostel
关键词:
摘要: Purpose Imatinib induces sustained remissions in patients with chronic myelogenous leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the issues cure, long-term imatinib tolerability, and resistance. We therefore asked whether interferon alfa-2a (IFN) alone could maintain molecular achieved by a prior combination therapy IFN. Patients Methods was stopped 20 who had concomitantly been pretreated IFN for median 2.4 years (range, 0.2 4.8 years) 2.5 4.9 years), respectively. After discontinuation, remission status monitored monthly quantitative analysis peripheral-blood BCR-ABL mRNA levels using real-time polymerase chain reaction. Proteinase-3 expression proteinase-3–specific cytotoxic T cells (CTLs) were longitudinally measured assess putative markers response. Results With time after ima...
sci-hub.se 参考文章(40)
J Molldrem, S Dermime, K Parker, YZ Jiang, D Mavroudis, N Hensel, P Fukushima, AJ Barrett, Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood. ,vol. 88, pp. 2450- 2457 ,(1996) , 10.1182/BLOOD.V88.7.2450.BLOODJOURNAL8872450
Jeffrey J. Molldrem, Peter P. Lee, Changqing Wang, Kyrie Felio, Hagop M. Kantarjian, Richard E. Champlin, Mark M. Davis, Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nature Medicine. ,vol. 6, pp. 1018- 1023 ,(2000) , 10.1038/79526
Brian J. Druker, Elisabeth Buchdunger, Thomas Meyer, Marcel Müller, Nicholas B. Lydon, Helmut Mett, Jürg Zimmermann, Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative Cancer Research. ,vol. 56, pp. 100- 104 ,(1996)
HJ Kolb, A Schattenberg, JM Goldman, B Hertenstein, N Jacobsen, W Arcese, P Ljungman, A Ferrant, L Verdonck, D Niederwieser, Graft-Versus-Leukemia Effect of Donor Lymphocyte Transfusions in Marrow Grafted Patients Blood. ,vol. 86, pp. 2041- 2050 ,(1995) , 10.1182/BLOOD.V86.5.2041.BLOODJOURNAL8652041
Susan M. Graham, Heather G. Jørgensen, Elaine Allan, Charlie Pearson, Michael J. Alcorn, Linda Richmond, Tessa L. Holyoake, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood. ,vol. 99, pp. 319- 325 ,(2002) , 10.1182/BLOOD.V99.1.319
F J Giles, M O'Dwyer, R Swords, Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. ,vol. 23, pp. 1698- 1707 ,(2009) , 10.1038/LEU.2009.111
Andreas Burchert, Andreas Neubauer, Interferon alpha and T-cell responses in chronic myeloid leukemia. Leukemia & Lymphoma. ,vol. 46, pp. 167- 175 ,(2005) , 10.1080/10428190400012029
Jorge Cortes, Susan O'Brien, Hagop Kantarjian, Discontinuation of imatinib therapy after achieving a molecular response. Blood. ,vol. 104, pp. 2204- 2205 ,(2004) , 10.1182/BLOOD-2004-04-1335
Michael W. N. Deininger, Tessa L. Holyoake, Can we afford to let sleeping dogs lie Blood. ,vol. 105, pp. 1840- 1841 ,(2005) , 10.1182/BLOOD-2004-12-4764
Toru Kiguchi, Tetsuzo Tauchi, Yoshikazu Ito, Keisuke Miyazawa, Yukihiko Kimura, Kazuma Ohyashiki, Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leukemia Research. ,vol. 33, pp. 506- 508 ,(2009) , 10.1016/J.LEUKRES.2008.04.018